نبذة مختصرة : Myotonic dystrophy type 1 (DM1) is a complex rare disorder characterized by progressive muscle dysfunction, involving weakness, myotonia, and wasting, but also exhibiting additional clinical signs in multiple organs and systems. Central dysregulation, caused by an expansion of a CTG trinucleotide repeat in the DMPK gene's 3' UTR, has led to exploring various therapeutic approaches in recent years, a few of which are currently under clinical trial. However, no effective disease-modifying treatments are available yet. In this study, we demonstrate that treatments with boldine, a natural alkaloid identified in a large-scale Drosophila-based pharmacological screening, was able to modify disease phenotypes in several DM1 models. The most significant effects include consistent reduction in nuclear RNA foci, a dynamic molecular hallmark of the disease, and noteworthy anti-myotonic activity. These results position boldine as an attractive new candidate for therapy development in DM1.
Relation: International Journal Of Molecular Sciences, 2023, vol. 24, num. 12, p. 9820; Álvarez-Abril, M.C.; García-Alcover, I.; Colonques-Bellmunt, J.; Garijo, R.; Pérez-Alonso, M.; Artero, R.; López-Castel, A. Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice. Int. J. Mol. Sci. 2023, 24, 9820. https://doi.org/10.3390/ijms24129820; https://hdl.handle.net/10550/95600; 160773; https://www.mdpi.com/1422-0067/24/12/9820
No Comments.